Neurosetta

Neurosetta is a biotechnology company that commercializes RosetteArray technology, a human stem cell-derived platform designed for high-throughput screening and disease modeling. The company utilizes micropatterned well plates, which incorporate specialized surface chemistry to induce the formation of neural tissues such as brain and spinal cord rosettes. By seeding these plates with human pluripotent stem cells or neuromesodermal progenitors, the platform enables researchers to study early human neurodevelopment, assess chemical or drug toxicity, and explore the impacts of genetic backgrounds in a reproducible and scalable manner.

This technology provides pharmaceutical, chemical, and research organizations with a tool to identify potential neurodevelopmental risks earlier in the development pipeline, potentially reducing costs and minimizing safety vulnerabilities. Neurosetta offers both standardized assays and custom services, including drug discovery screens and the development of patient-derived models for neurological conditions. The company holds exclusive rights to the underlying patented technology and operates from the Wisconsin Institute for Discovery, focusing on advancing precision medicine and chemical safety.